Khattar Jack A. — SEC Form 4 filings
SEC reporting owner CIK 1539937. 42 Form 4 filings on record with FilingPulse; latest filed 2026-08-14.
Transaction summary — filings shown
Covers all 42 filings on record, filed 2024-02-22 to 2026-08-14. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): none reported.
- Open-market sales (code S, non-derivative): 22 legs across 16 filings — 691,100 shares, $29,431,088 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 96.
- Largest priced transaction: sale of 125,000 shares @ $36.68 ($4,585,000) in SUPERNUS PHARMACEUTICALS, INC., filed 2024-11-08.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | President, CEO, Director | 36 | — | 22 legs · 691,100 sh · $29,431,088 | 85 |
| scPharmaceuticals Inc. (SCPH) | Director | 3 | — | — | 7 |
| COGNITION THERAPEUTICS INC (CGTX) | Director | 3 | — | — | 4 |
Form 4 filings — Khattar Jack A.
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-08-14 | 4 | SUPERNUS PHARMACEUTICALS, INC. (SUPN) | Option exercise (M): 29,849 @ $0 · Tax withholding (F): 12,642 @ $46.57 · Option exercise (M): 29,849 (derivative) @ $0 | EDGAR |
| 2026-07-31 | 4 | SUPERNUS PHARMACEUTICALS, INC. (SUPN) | Grant/award (A): 29,849 (derivative) @ $0 | EDGAR |
| 2026-06-22 | 4 | COGNITION THERAPEUTICS INC (CGTX) | Grant/award (A): 25,000 @ $0 | EDGAR |
| 2026-03-16 | 4 | SUPERNUS PHARMACEUTICALS, INC. (SUPN) | Other (J): 12,500 · Other (J): 12,500 · Sale (S): 24,138 @ $50.09 · Sale (S): 10,742 @ $51 · Sale (S): 120 @ $51.75 | EDGAR |
| 2026-03-10 | 4 | SUPERNUS PHARMACEUTICALS, INC. (SUPN) | Option exercise (M): 38,640 @ $0 · Tax withholding (F): 16,574 @ $54.73 · Option exercise (M): 38,640 (derivative) @ $0 | EDGAR |
| 2026-03-03 | 4 | SUPERNUS PHARMACEUTICALS, INC. (SUPN) | Grant/award (A): 38,640 (derivative) @ $0 | EDGAR |
| 2026-02-20 | 4 | SUPERNUS PHARMACEUTICALS, INC. (SUPN) | Grant/award (A): 341,610 (derivative) @ $0 | EDGAR |
| 2025-10-10 | 4 | SUPERNUS PHARMACEUTICALS, INC. (SUPN) | Option exercise (M): 81,250 @ $25.30 · Sale (S): 58,371 @ $50.55 · Sale (S): 1,529 @ $51.46 · Option exercise (M): 81,250 (derivative) @ $0 | EDGAR |
| 2025-10-07 | 4 | scPharmaceuticals Inc. (SCPH) | Code (U): 5,000 · Disposition to issuer (D): 30,000 (derivative) @ $0 · Disposition to issuer (D): 19,750 (derivative) @ $0 · Disposition to issuer (D): 16,300 (derivative) @ $0 · Disposition to issuer (D): 6,124 (derivative) @ $0 | EDGAR |
| 2025-10-03 | 4 | SUPERNUS PHARMACEUTICALS, INC. (SUPN) | Option exercise (M): 2,267 @ $25.30 · Sale (S): 1,904 @ $48.06 · Option exercise (M): 2,267 (derivative) @ $0 | EDGAR |
| 2025-10-03 | 4 | SUPERNUS PHARMACEUTICALS, INC. (SUPN) | Option exercise (M): 20,000 @ $0 · Tax withholding (F): 7,796 @ $46.21 · Option exercise (M): 19,320 @ $0 · Tax withholding (F): 7,529 @ $46.21 · Option exercise (M): 20,000 (derivative) @ $0 · Option exercise (M): 19,320 (derivative) @ $0 | EDGAR |
| 2025-10-02 | 4 | SUPERNUS PHARMACEUTICALS, INC. (SUPN) | Option exercise (M): 53,785 @ $25.30 · Sale (S): 40,173 @ $48.07 · Option exercise (M): 53,785 (derivative) @ $0 | EDGAR |
| 2025-10-01 | 4 | SUPERNUS PHARMACEUTICALS, INC. (SUPN) | Option exercise (M): 11,510 @ $25.30 · Sale (S): 8,588 @ $48.25 · Option exercise (M): 11,510 (derivative) @ $0 | EDGAR |
| 2025-09-30 | 4 | SUPERNUS PHARMACEUTICALS, INC. (SUPN) | Option exercise (M): 13,688 @ $25.30 · Sale (S): 10,235 @ $48.02 · Option exercise (M): 13,688 (derivative) @ $0 | EDGAR |
| 2025-09-24 | 4 | SUPERNUS PHARMACEUTICALS, INC. (SUPN) | Option exercise (M): 47,940 @ $12.98 · Sale (S): 29,513 @ $47.23 · Option exercise (M): 47,940 (derivative) @ $0 | EDGAR |
| 2025-09-23 | 4 | SUPERNUS PHARMACEUTICALS, INC. (SUPN) | Option exercise (M): 27,060 @ $12.98 · Sale (S): 16,587 @ $47.02 · Option exercise (M): 27,060 (derivative) @ $0 | EDGAR |
| 2025-09-12 | 4 | SUPERNUS PHARMACEUTICALS, INC. (SUPN) | Grant/award (A): 20,000 (derivative) @ $0 · Grant/award (A): 19,320 (derivative) @ $0 | EDGAR |
| 2025-09-09 | 4 | SUPERNUS PHARMACEUTICALS, INC. (SUPN) | Option exercise (M): 8,074 @ $25.30 · Sale (S): 6,322 @ $46.29 · Option exercise (M): 8,074 (derivative) @ $0 | EDGAR |
| 2025-09-08 | 4 | SUPERNUS PHARMACEUTICALS, INC. (SUPN) | Option exercise (M): 73,176 @ $25.30 · Sale (S): 55,578 @ $46.01 · Option exercise (M): 73,176 (derivative) @ $0 | EDGAR |
| 2025-08-29 | 4 | SUPERNUS PHARMACEUTICALS, INC. (SUPN) | Option exercise (M): 17,195 @ $12.98 · Sale (S): 10,650 @ $45.05 · Option exercise (M): 38,779 @ $12.98 · Sale (S): 24,150 @ $45.12 · Option exercise (M): 17,195 (derivative) @ $0 · Option exercise (M): 38,779 (derivative) @ $0 | EDGAR |
| 2025-08-27 | 4 | SUPERNUS PHARMACEUTICALS, INC. (SUPN) | Option exercise (M): 1,611 @ $12.98 · Sale (S): 1,000 @ $45 · Option exercise (M): 1,611 (derivative) @ $0 | EDGAR |
| 2025-08-26 | 4 | SUPERNUS PHARMACEUTICALS, INC. (SUPN) | Option exercise (M): 2,415 @ $12.98 · Sale (S): 1,500 @ $45 · Option exercise (M): 2,415 (derivative) @ $0 | EDGAR |
| 2025-08-08 | 4 | SUPERNUS PHARMACEUTICALS, INC. (SUPN) | Option exercise (M): 60,000 @ $12.98 · Sale (S): 38,500 @ $40.24 · Option exercise (M): 60,000 @ $12.98 · Sale (S): 38,000 @ $42 · Option exercise (M): 81,250 @ $25.30 · Sale (S): 63,500 @ $43.12 · +3 more | EDGAR |
| 2025-06-23 | 4 | COGNITION THERAPEUTICS INC (CGTX) | Grant/award (A): 34,000 @ $0 | EDGAR |
| 2025-06-05 | 4 | scPharmaceuticals Inc. (SCPH) | Grant/award (A): 30,000 (derivative) @ $0 | EDGAR |
| 2025-04-03 | 4 | SUPERNUS PHARMACEUTICALS, INC. (SUPN) | Other (J): 16,850 · Other (J): 16,850 | EDGAR |
| 2025-03-11 | 4 | SUPERNUS PHARMACEUTICALS, INC. (SUPN) | Option exercise (M): 35,000 @ $0 · Tax withholding (F): 16,805 @ $32.06 · Option exercise (M): 35,000 (derivative) @ $0 | EDGAR |
| 2025-03-07 | 4 | SUPERNUS PHARMACEUTICALS, INC. (SUPN) | Option exercise (M): 38,640 @ $0 · Tax withholding (F): 18,581 @ $39.11 · Option exercise (M): 38,640 (derivative) @ $0 | EDGAR |
| 2025-03-04 | 4 | SUPERNUS PHARMACEUTICALS, INC. (SUPN) | Grant/award (A): 35,000 (derivative) @ $0 | EDGAR |
| 2025-02-21 | 4 | SUPERNUS PHARMACEUTICALS, INC. (SUPN) | Grant/award (A): 331,660 (derivative) @ $0 | EDGAR |
| 2025-02-19 | 4 | SUPERNUS PHARMACEUTICALS, INC. (SUPN) | Grant/award (A): 38,640 (derivative) @ $0 | EDGAR |
| 2024-12-30 | 4 | SUPERNUS PHARMACEUTICALS, INC. (SUPN) | Option exercise (M): 38,640 @ $0 · Tax withholding (F): 18,567 @ $35.59 · Option exercise (M): 14,000 @ $0 · Tax withholding (F): 6,666 @ $35.59 · Option exercise (M): 38,640 (derivative) @ $0 · Option exercise (M): 14,000 (derivative) @ $0 | EDGAR |
| 2024-12-26 | 4 | SUPERNUS PHARMACEUTICALS, INC. (SUPN) | Grant/award (A): 14,000 (derivative) @ $0 · Grant/award (A): 38,640 (derivative) @ $0 | EDGAR |
| 2024-11-12 | 4 | SUPERNUS PHARMACEUTICALS, INC. (SUPN) | Option exercise (M): 125,000 @ $9.13 · Sale (S): 125,000 @ $36.29 · Option exercise (M): 125,000 (derivative) @ $0 | EDGAR |
| 2024-11-08 | 4 | SUPERNUS PHARMACEUTICALS, INC. (SUPN) | Option exercise (M): 125,000 @ $9.13 · Sale (S): 125,000 @ $36.68 · Option exercise (M): 125,000 (derivative) @ $0 | EDGAR |
| 2024-09-03 | 4 | SUPERNUS PHARMACEUTICALS, INC. (SUPN) | Option exercise (M): 21,000 @ $0 · Tax withholding (F): 10,045 @ $34.90 · Option exercise (M): 21,000 (derivative) @ $0 | EDGAR |
| 2024-08-27 | 4 | SUPERNUS PHARMACEUTICALS, INC. (SUPN) | Grant/award (A): 21,000 (derivative) @ $0 | EDGAR |
| 2024-06-13 | 4 | scPharmaceuticals Inc. (SCPH) | Grant/award (A): 19,750 (derivative) @ $0 | EDGAR |
| 2024-06-11 | 4 | COGNITION THERAPEUTICS INC (CGTX) | Grant/award (A): 8,500 @ $0 · Grant/award (A): 8,500 (derivative) @ $0 | EDGAR |
| 2024-02-29 | 4 | SUPERNUS PHARMACEUTICALS, INC. (SUPN) | Option exercise (M): 35,000 @ $0 · Tax withholding (F): 16,788 @ $27.94 · Option exercise (M): 35,000 (derivative) @ $0 | EDGAR |
| 2024-02-26 | 4 | SUPERNUS PHARMACEUTICALS, INC. (SUPN) | Grant/award (A): 322,000 (derivative) @ $0 · Grant/award (A): 35,000 (derivative) @ $0 | EDGAR |
| 2024-02-22 | 4 | SUPERNUS PHARMACEUTICALS, INC. (SUPN) | Other (J): 16,500 · Other (J): 16,500 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2024-01-11 and is expanding backward through EDGAR history — earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1539937 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. API docs →